Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | AMY2A | P04746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Griffonin SCHEMBL28797041 | 1.00 | MAPT (0.43) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| Griffonin SCHEMBL20995242 | 1.00 | MAPT (0.43) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| Griffonin SCHEMBL21034847 | 1.00 | MAPT (0.43) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL21035198 | 0.92 | PTPN1 (0.35) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL29586077 | 0.89 | PTPN1 (0.40) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL21035195 | 0.80 | PTPN1 (0.45) | PTPN1L3MBTL1MEN1KMT2ATYR | |
| SCHEMBL30615017 | 0.79 | PTPN1 (0.44) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL30089929 | 0.79 | PTPN1 (0.44) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| SCHEMBL21034846 | 0.79 | L3MBTL1 (0.42) | MAPTPTPN1L3MBTL1MEN1KMT2A | |
| Trehalose SCHEMBL166078 | 0.69 | MAPT (0.56) | MAPTPTPN1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179408-B2 | Use of cyanoglucosides and pharmaceutical formulations thereof in the treatment of diabetes | UNIVERSITÉ DE GENÈVE (CH) | 2021-11-23 | — | — | US | disclosed |
| US-20190160085-A1 | USE OF CYANOGLUCOSIDES AND PHARMACEUTICAL FORMULATIONS THEREOF IN THE TREATMENT OF DIABETES | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO (BR) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160085-A1 | USE OF CYANOGLUCOSIDES AND PHARMACEUTICAL FORMULATIONS THEREOF IN THE TREATMENT OF DIABETES | SLC5A1, SLC5A2, GYS2 | MAPT 2428/4885PTPN1 3362/4885L3MBTL1 1912/4885 |
| US-11179408-B2 | Use of cyanoglucosides and pharmaceutical formulations thereof in the treatment of diabetes | SLC5A2, SLC5A1, GYS2 | MAPT 2343/4885PTPN1 3241/4885L3MBTL1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.